

Review Article

Prognostic and clinicopathological value of Gli1 expression in esophageal squamous cell carcinoma: a meta-analysis

Yuanfu Yang^{1,2*}, Yuzhu Hu^{3*}, Yashan Yang^{5,6*}, Ting Yu³, Mengting Li⁴, Xia Liu⁴, Ting Luo¹

¹Department of Head & Neck and Mammary Oncology and Department of Medical Oncology, Laboratory of Molecular Diagnosis of Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, PR China; ²Department of Medical Oncology, Dujiangyan People's Hospital, Dujiangyan 611830, PR China;

³Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, PR China;

⁴Department of Abdominal Cancer, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, PR China; ⁵Southwest Medical University, Luzhou 646000, PR China; ⁶Sichuan Integrative Medical Hospital, Chengdu 610042, PR China. *Equal contributors.

Received October 31, 2017; Accepted January 4, 2018; Epub March 15, 2018; Published March 30, 2018

Abstract: Lots of clinical and basic researches focused on Glioma associated oncogene 1 (Gli1) which plays an important role on the development and prognosis of esophageal squamous cell carcinoma (ESCC), but did not reach consensus. This study aims to provide valuable reference for prognosis estimation and therapeutic approach in ESCC patients. Eleven studies with 749 cases of esophageal carcinoma were included to analyze the relationship between Gli1 expression and clinicopathological features, 3/5-year survival, and overall survival (OS) using pooled risk ratios (RRs) and hazard ratio (HR) with 95% confidence intervals (CIs). This meta-analysis suggested that up-regulated Gli1 was associated with advanced clinical stage (RR = 3.71, 95% CI: [2.34, 5.86]), higher T stage (RR = 3.43, 95% CI: [1.41, 8.36]), and lymph node metastasis (RR = 1.98, 95% CI: [1.22, 3.21]). This study also indicated that positive Gli1 expression was associated with poorer survival in ESCC, with 3-year survival (RR = 2.37, 95% CI: [1.57, 3.60]), 5-year survival (RR = 3.40, 95% CI: [2.21, 5.25]) and overall survival (OS) (HR = 2.42, 95% CI: [1.76, 3.34]). On the whole, the over-expression of Gli1 could predict poor survival in ESCC patients and detection of Gli1 may provide a new thought for monitoring the prognosis of ESCC.

Keywords: Gli1 over-expression, esophageal squamous cell carcinoma, prognosis

Introduction

Cancer has been a costly public health burden all around the world. Esophageal carcinoma is the sixth most common cause of cancer death in the world [1, 2]. Approximately half of the newly diagnosed esophageal carcinoma happened in China [3]. Esophageal squamous cell carcinoma (ESCC) is the major pathological type in Asian countries, which accounts for approximate 90% of esophageal carcinoma [4]. Most of esophageal carcinoma patients have advanced stages at initial diagnosis. Nevertheless, the overall 5-year survival varies from 15% to 25% despite of the improvement of diagnostic techniques and treatment approaches [2]. Although the same therapy was given to

esophageal carcinoma patients in the same stage, the clinical outcomes vary from each other, which may be attributed to diversity of biological behavior of tumors [5]. Studies have shown that some genetic alterations were related to the progression of esophageal carcinoma, while seldom of them have been clearly demonstrated to be correlated with clinicopathological features of esophageal carcinoma [6]. Consequently, there is a need to find better prognostic indicator in order to improve treatment for esophageal carcinoma.

Aberrant activation of Sonic Hedgehog (Shh) signaling pathway is verified to be associated with tumorigenesis and tumor progression in malignant cancers, such as skin tumor [7, 8],

pancreatic carcinoma [9, 10], esophageal carcinoma [11], lymphoma [12], brain carcinoma [13], colonic carcinoma [14], gastric carcinoma [15], prostate carcinoma [16]. Smoothed (Smo) protein is a transmembrane protein acting as on-off switch in Shh signaling pathway. Gli1 is a downstream transcriptional factor of Smo protein which can transduce extracellular Shh signal into intracellular Gli1 signal and elicit Gli1-dependent transcription of intranuclear target genes to activate Shh signaling pathway [17]. Thus abnormal up-regulated expression of Gli1 caused by aberrant activation of Shh signaling pathway could be related to development of malignant cancers.

Gli1 has been reported to be an unfavorable prognostic factor in stomach, pancreas, breast, ovary, liver and bladder cancers [18-25]. Overexpression of Gli1 is common in Barrett's and adenocarcinoma of esophagus [26-28]. Gli1 could contribute to invasion and metastasis of ESCC through promoting epithelial-to-mesenchymal transition (EMT) [29, 30], which is an early event in the metastatic progression of a number of types of epithelial cancers [31, 32]. Moreover, Gli1 can also bind to the promoter and enhance expression of cyclin-dependent kinase 2 (CDK2), which is a cell cycle regulator, promoting cell proliferation in esophageal tumorigenesis [26]. Furthermore, Gli1 expression has been reported to be associated with lymph node metastasis, tumor progression and resistance to chemo-radiotherapy in esophageal carcinoma [18, 27, 28]. Yoshikawa suggested that Gli1 nuclear expression is a strong independent predictor of early relapse and poor prognosis in ESCC after chemo-radiotherapy [11]. However, potential predictive role of Gli1 in prognosis of esophageal carcinoma remains unclear. Our study aims at integrating evidence to elucidate relationship between Gli1 expression and clinicopathological features of esophageal carcinoma, so as to provide evidence for prognosis estimation and therapeutic approach.

Methods

Literature search strategy

MEDLINE, EMBASE, PubMed, the Cochrane Library, and the China National Knowledge Infrastructure were searched for the studies

by using the key words at the last time on November 11, 2016. The search strategy included the following keywords variably combined with "esophagus cancer (or esophagus carcinoma)", "Gli1 (or Glioma associated oncogene 1)" and "prognosis (or prognostic)". We also searched the studies referring to the reference of the eligible studies or relevant reviews. Finally, we removed duplicates and got the initial articles.

Study selection criteria

We considered studies as eligible if they met all of the following inclusion criteria: (1) esophagus cancer patients were diagnosed by pathological examination; (2) expressions of Gli1 were measured; (3) studies could provide adequate information of the survival analysis or clinical features of patients related to the Gli1 expression. Review articles, case reports, laboratory articles, letters, or the papers lack of necessary information for what we needed were excluded.

Data extraction


Articles were reviewed independently by two investigators for article inclusion and exclusion according to the criteria we mentioned above. Disagreements were resolved by consultation with the third investigator. We extracted the HR and 95% confidence interval (CI), *p* value, Kaplan-Meier survival curves of survival outcomes, first author, publication year, study design, study size, origin of population, patients age and sexuality, clinical stage, T stage, methods to detect Gli1, definition of Gli1 positive and expression rate in each studies.

Quality assessment

Two investigators evaluated the quality of the eligible studies independently by the Newcastle-Ottawa Scale (NOS). The NOS score (full score = 9) more than 5 was defined as high quality study. Controversial studies were discussed together by the whole team.

Statistical methods

The log (HR) and standard error of the log (HR) were used for aggregation of the survival results. In addition to directly extraction, the



necessary statistics were also calculated based on the available data with methods proposed by Parmar [33], Williamson [34], and Tierney [35]. Multivariate Cox hazard regression analysis data were preferred in our analysis, if not available, we extracted Univariate Cox hazard regression analysis or Kaplan-Meier survival curves by applying Engauge Digitizer version 4.1 with log-rank p value of survival outcomes instead. Then further meta-analysis of OS was performed. Calculation was accomplished by the software designed by Matthew Sydes and Jayne Tierney with their methods (Medical Research Council Clinical Trials Unit, London, UK)[35]. Risk ratio (RR) was used to evaluate the association between positive Gli1 expression and clinical features, such as gender (male vs. female), histological grade (poor/undifferentiated vs. well/moderate), T stage (T3/T4 vs. T1/T2), lymph node metastasis (Yes vs. No), clinical stage (III/IV vs. I/II), etc.

Effect of Gli1 expression on survival outcome and the correlation between Gli1 expression and the clinical features were estimated by Forrest plots. Obvious heterogeneity was defined as $p < 0.05$ for the χ^2 test or $I^2 > 50\%$. When there was no statistically significant heterogeneity, a fixed effect model was used for analysis; otherwise, a random effect model was used [36]. Begg's funnel plots and Egger's tests were used to evaluate publication bias, and $p > 0.05$ was considered no potential pub-

lication bias [37]. All above calculations were performed using Stata version 12.0 (Stata Corporation, College Station, TX, USA).

Results

Eligible studies

Total 448 published articles including 213 reviews were yielded by searching in the databases of MEDLINE, EM-BASE, PubMed, the Cochrane Library, and the China National Knowledge Infrastructure. We screened abstracts of the rest 235 articles and excluded 120 articles for laboratory research, 42 articles for other cancers and 31 articles for

other diseases. Then remaining 42 articles were selected for detailed evaluation. Among them, 20 were removed for analyzing survival focused on unrelated biomarkers, 10 were removed for data not available for meta-analysis and 1 was deleted for possible duplicated data. Finally, 11 eligible articles [11, 18, 28, 38-45] were analyzed in our study. Flow chart of study identification is presented in **Figure 1**.

Study characteristics

We collected data from eleven studies including 749 cases of esophageal carcinoma (744 ESCC and 5 esophageal adenocarcinomas) from China, Japan and South Korea. They were all ranged from 2006 to 2016. Gli1 expression was evaluated by immunological histological chemistry (IHC) method except for Li's study [40] by reverse transcription-polymerase chain reaction (RT-PCR) method. The sample size ranged from 12 to 127. Total six studies [11, 18, 28, 38, 42, 45] analyzed the relationship between Gli1 expression and OS, two [11, 45] of which also investigated correlation between Gli1 expression and disease free survival (DFS) and one [28] of which also investigated Gli1 expression and progression free survival (PFS). Further detailed features were presented in **Table 1**, quality assessments were listed in **Table 2** and main outcomes were summarized in **Table 3**.

Prognostic biomarker in ESCC

Table 1. Characteristics of all identified studies

First author	Year	Country	Pathological type	Number (M/F)	Mean age	Method	Antibody source	Definition of Gil1 positive	Expression rate (%)	Survival analysis
Yang ZT	2016	Korea	ESCC	127 (120/7)	NR	IHC	Abcam	Weak staining $\geq 50\%$ or moderate staining $\geq 20\%$	28.35	OS, DFS
Zhu WG	2011	China	ESCC	100 (85/15)	55	IHC	Santa Cruz Biotech	$\geq 10\%$	72	OS, DPFS, LPFS
Mori Y	2006	Japan	ESCC	104 (92/12)	63	IHC	C-18 Santa Cruz	$> 25\%$	50	OS
Wei LY	2011	China	ESCC (30)/Ade (5)	35 (29/6)	60	IHC	Eugene	NR	71.4	OS
Yoshikawa R	2008	Japan	ESCC	69 (58/11)	60.7	IHC	Sana Cruz Biotech	$\geq 5\%$	10.14	OS, DFS
Cui HW	2015	China	ESCC	12 (9/3)	53.61	IHC	NR	NR	83.33	NR
Li JP	2013	China	ESCC	68 (44/24)	54	RT-PCR	NR	Score $> 3^*$	70.60%	NR
Ju L	2013	China	ESCC	50 (50/0)	62	IHC	Santa Cruz Biotech	NR	68	NR
Sun B	2011	China	ESCC	60 (36/24)	60.6	IHC	Bioss antibodies	$\geq 5\%$	88.33	NR
Wei LY	2016	China	ESCC	88 (75/13)	56.52	IHC	Eugene	NR	71.59	OS
Xiao F	2016	China	ESCC	36 (20/16)	NR	IHC	Santa Cruz Biotech	$\geq 5\%$	55.6	NR

NR, not reference; IHC, immunohistochemistry; RT-PCR, reverse transcription-polymerase chain reaction; ESCC, esophageal squamous cell carcinomas; Ade, adenocarcinoma; DFS, disease free survival; OS, overall survival; LPFS, loco-regional progression free survival; DPFS, distant progression free survival; NOS, Newcastle-Ottawa Scale. *IHC staining score: 1, 0~10%; 2, 10% ~ 50%; 3, >50%. The dyeing strength score: 0 = undetectable; 1 = yellow (blue); 2 = moderate yellow (blue); 3 = brown (purple blue). The final score = IHC staining score x the dyeing strength core, and total score of 0 ~ 3 divided into negative, more than 3 is positive.

Table 2. Quality assessment of all identified studies

First author	Representativeness of the exposed cohort	Selection of the non-exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design	Assessment of outcome	Enough follow-up for outcomes to occur	Adequacy of follow up of cohorts	NOS score
Yang ZT	1	1	1	1	1	1	1	1	8
Zhu WG	1	0	1	1	1	1	1	1	7
Mori Y	1	0	1	1	1	1	1	0	6
Wei LY	1	0	1	1	1	1	0	1	6
Yoshikawa R	1	0	1	1	1	1	1	1	7
Cui HW	1	1	1	1	1	1	0	0	6
Li JP	1	1	1	1	1	1	0	0	6
Ju L	1	1	1	1	1	1	0	0	6
Sun B	1	1	1	1	1	1	0	0	6
Wei LY	1	0	1	1	1	1	1	1	7
Xiao F	1	1	1	1	1	1	0	0	6

Table 3. Summary of the outcomes presented in this meta-analysis.

Group	No. of studies	No. of total patients	RR/HR (95% CI) (Gli1 positive VS. Gli1 negative)	P for heterogeneity	I ²	References
Gender (male vs. female)	8	562	1.06 (0.62, 1.80)	0.731	0.0%	[18, 28, 39, 40, 41, 43-45]
Histological grade (poor/undifferentiated vs. well/moderate)	8	542	1.26 (0.58, 2.75)	0.037	53.2%	[18, 28, 38-41, 44, 45]
Clinical stage (III/IV vs. I/II)	7	393	3.71 (2.34, 5.86)	0.937	0.0%	[18, 38-40, 42-44]
T stage (T3/T4 vs. T1/T2)	4	299	2.23 (1.87, 5.60)	0.077	56.2%	[18, 40, 43, 44]
Lymph node metastasis (Yes vs. No)	7	514	1.98 (1.22, 3.21)	0.091	45%	[28, 38, 40, 41, 43-45]
3-year survival	6	523	2.37 (1.57, 3.60)	0.509	0.0%	[11, 18, 28, 40, 41, 43]
5-year survival	5	454	3.40 (2.21, 5.25)	0.244	26.6%	[18, 28, 40, 41, 43]
OS	6	523	2.42 (1.76, 3.34)	0.385	5.0%	[11, 18, 28, 40, 41, 43]

Correlation between Gli1 expression and clinicopathological features

Gender and histological grade: Total eight studies involving 562 patients were used to analyze the correlation between Gli1 expression and gender (male vs. female), histological grade (poor differentiated vs. well/moderate differentiated) respectively, as shown in **Figure 2A** and **2B**. Results showed that no significant relationship was discovered between Gli1 expression and gender (RR = 1.06, 95% CI: [0.62, 1.80]), histological grade (RR = 1.26, 95% CI: [0.58, 2.75]) in ESCC patients. A fixed effect model was applied for gender considering the heterogeneity ($I^2 = 0.0\%$, $P = 0.731$), while a random effect model was used for histological grade due to the obvious heterogeneity ($I^2 = 53.2\%$, $P = 0.037$).

Clinical Stage: There were seven studies [18, 38-40, 42-44] including 393 patients offering data of clinical stage (stage III/IV vs. stage I/II) and Gli1 expression. Results disclosed that overexpression of Gli1 was more prevalent in stage III/IV when compared with that in stage I/II (RR = 3.71, 95% CI: [2.34, 5.86]) (**Figure 2C**). A fixed effect model was applied considering the heterogeneity ($I^2 = 0.0\%$, $P = 0.937$).

T stage: Four studies [18, 42-44] containing data of T stage (T3/T4 vs. T1/T2) and Gli1 expression levels were included for analyzing correlation between Gli1 expression level and T stage. Result showed up-regulation of Gli1 expression is significantly associated with advanced T stage (T3/T4) (RR = 3.43, 95% CI: [1.41, 8.36]) (**Figure 2D**). A random effect model was applied considering the heterogeneity ($I^2 = 56.2\%$, $P = 0.077$).

Lymph node metastasis: Relation between status of lymph node metastasis (positive vs. neg-

ative) and Gli1 expression was analyzed based on data provided by seven studies [28, 40-45]. Result showed positive lymph node metastasis was significantly associated with up-regulated Gli1 expression (RR = 1.98, 95% CI: [1.22, 3.21]) (**Figure 2E**). A fixed effect model was applied considering the heterogeneity ($I^2 = 45\%$, $P = 0.091$).

Correlation between Gli1 expression and 3-year and 5-year survival

Total six studies [11, 18, 28, 42, 43, 45] provided 3-year survival data and five of them [18, 28, 42, 43, 45] provided 5-year survival data. The results displayed mild heterogeneity (3-year survival: $I^2 = 0.0\%$, $P = 0.509$; 5-year survival: $I^2 = 26.6\%$, $P = 0.244$), so a fixed effect model was applied to calculate the pooled RRs and their corresponding 95% CIs. Elevated Gli1 expression level was associated with poor 3-year survival (RR = 2.37, 95% CI: [1.57, 3.60]) and 5-year survival (RR = 3.40, 95% CI: [2.21, 5.25]) in ESCC patients, as shown in **Figure 3**.

Correlation between Gli1 expression and OS

Data involving OS were extracted from six studies [11, 18, 28, 42, 43, 45] including 523 patients. Given the mild heterogeneity ($I^2 = 5.0\%$, $P = 0.385$), a fixed effect model was used to calculate the pooled HR and its corresponding 95% CI. The pooled HR for OS was 2.42 (95% CI: [1.76, 3.34]) demonstrating that Gli1 over-expression was associated with poor OS of ESCC patients.

Publication bias

Both Begg's funnel plot and Egger's test were used to assess the publication bias in all studies evaluating gender, histological grade, clinical stage, T stage, lymph node metastasis,

Prognostic biomarker in ESCC




Figure 2. Forrest plots of RRs for correlation between Gli1 expression and clinicopathological features. (A) gender, (B) histological grade, (C) clinical stage, (D) T stage, (E) lymph node metastasis.

3-year and 5-year survival and OS, respectively (**Figure 4**). The Begg's funnel plot did not demonstrate any evidence of statistically significant asymmetry in the meta-analysis of gender ($p = 0.621$), histological grade ($p = 0.621$), clinical stage ($p = 0.881$), T stage ($p = 0.497$), lymph node metastasis ($p = 0.099$), 3-year and 5-year survival ($p = 0.243$) and OS ($p = 0.188$). Moreover, there was also no evidence of publication bias in Egger's test of gender ($p = 0.928$), histological grade ($p = 0.749$), clinical stage ($p = 0.502$), T stage ($p = 0.717$), lymph node metastasis ($p = 0.120$), 3-year and 5-year survival ($p = 0.025$) and OS ($p = 0.286$).

Discussion

Gli1, as a key transcription factor of Shh signaling pathway, is proved to be associated with a variety of malignant tumors in recent years. Tremendous researches have disclosed correlations between Shh pathway and some classic signaling pathway of tumorigenesis and tumor progression [8, 10, 46-48], eliciting its potential role in predicting prognosis of malignant tumors and acting as potential target for cancer treatment. Although Gli1 is reported to be an unfavorable prognostic factor in some solid cancers like stomach, pancreas, breast, ovary,

Prognostic biomarker in ESCC




Figure 3. Forrest plots of RR and HR for Gli1 expression about the survival outcomes. (A) 3-year and 5-year survival, (B) OS.




Figure 4. Funnel graph for assessing the potential publication of this meta-analysis. (A) gender, (B) histological grade, (C) clinical stage, (D) T stage, (E) lymph node metastasis, (F) 3-year and 5-year survival, (G) OS.

liver and bladder cancers [18-25], it remains unclear that whether up-regulation of Gli1 expression is associated with unfavorable prognosis in patients suffering from esophageal

cancer. So far, there have been two meta-analyses analyzing Gli1 expression and prognosis of malignant cancers published. Cheng's study focused on summarizing prognostic role of Gli1

in all solid tumors with the defect of possible heterogeneities between different cancer types [49]. While Lu's study explained prognostic role of Gli1 over-expression in gastric cancer [19]. Thus our study is the first meta-analysis to expound that Gli1 is a reliably unfavorable prognostic factor in ESCC patients and revealed correlations between Gli1 expression and some clinicopathological features.

In our study, results demonstrated that up-regulated Gli1 expression was related with poor outcome in 3-year survival, 5-year survival and OS in ESCC patients. Gli1 expression was correlated with advanced clinical stage, higher T stage and positive lymph node metastasis of ESCC but unrelated to gender and histological grade. Enhanced expression of Gli1 was more common in patients at advanced stages or with lymph node metastasis, therefore Gli1 may be considered as a potential biomarker to predict prognosis in advanced stages of ESCC. Moreover, Yang's [45] study and Yoshikawa's [11] study reported Gli1 over-expression predicted worse DFS in esophageal cancer patients. Zhu's [28] study found Gli1 was correlated with shorter both locoregional progression free survival (LPFS) and distant progression free survival (DPFS). Despite eligible articles in our study involving DFS or PFS were very limited, Gli1 expression may be related with shorter DFS and PFS in ESCC according to these published data. In summary, our study supported that Gli1 indicated poor prognosis in ESCC patients.

Lymph node metastasis is one of the main metastasis modes of ESCC, and also one of the most common causes of recurrence and death in ESCC patients. Most patients with ESCC would have lymph node metastasis, at locations such as mediastinum, abdomen, trachea, hilum of lung and bronchi [50, 51]. Our research showed improved expression of Gli1 often accompanied with lymph node metastasis in ESCC patients. Therefore, doctors should pay more attention to the inspection of lymphatic drainage area in the examination of patients with the high expression of Gli1. Making early intervention such as preventive radiotherapy of lymphatic drainage area in ESCC patients without lymph node metastasis, whether can bring more benefits to the survival of patients, is very interesting. These may provide a new thought

for the clinical diagnosis and treatment decision for ESCC patients.

Although the satisfactory results were showed above, there were also several limitations in our meta-analysis. Firstly, there were lack of randomized controlled trials, and most studies included were retrospective studies. Secondly, the crowd of the researches was concentrated in Asia, so the clinical features and outcomes of this study are more applicable for Asian population. Thirdly, due to the differences of antibodies and definitions of Gli1 positive in the detection of the Gli1 expression, potential bias might occur in our analysis. Finally, there were 5 esophageal adenocarcinoma patients who could not be separated from our analysis. These short comes can be better solved with more relevant researches published.

Our meta-analysis integrated convincing evidence to elucidate relationship between Gli1 expression and prognosis of ESCC. The high expression of Gli1 could predict poor survival in patients with ESCC. Doctors should pay more attention to the patients with high expression of Gli1, who may occur with progression, invasion and metastasis. On the whole, our meta-analysis is the first one to explain Gli1 expression as aggressive biological behavior in ESCC patients, and the correlation between Gli1 expression and lymph node metastasis may have important significance on making treatment decisions. The detection of Gli1 provides more convincing evidences for guiding the diagnosis and estimating prognosis of ESCC patients.

Disclosure of conflict of interest

None.

Abbreviations

Gli1, Glioma associated oncogene 1; ESCC, esophageal squamous cell carcinoma; RRs, risk ratios; HR, hazard ratio; CIs, confidence intervals; OS, overall survival; Shh, Sonic Hedgehog; Smo, Smoothened; EMT, epithelial-to-mesenchymal transition; CDK2, cyclin-dependent kinase 2; IHC, immunological histological chemistry; RT-PCR, reverse transcription-polymerase chain reaction; DFS, disease free survival; PFS, progression free survival; LPFS, locoregional progression free survival; DPFS, distant progression free survival.

Address correspondence to: Dr. Ting Luo, Department of Head & Neck and Mammary Oncology and Department of Medical Oncology, Laboratory of Molecular Diagnosis of Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, PR China. Fax: +86-028-854-23278; Tel: +86-18602866299; E-mail: tina621@163.com

References

- [1] Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010; 127: 2893-2917.
- [2] Pennathur A, Gibson MK, Jobe BA and Luke-tich JD. Oesophageal carcinoma. *Lancet* 2013; 381: 400-412.
- [3] Holmes RS and Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. *Semin Radiat Oncol* 2007; 17: 2-9.
- [4] Qi YJ, Chao WX and Chiu JF. An overview of esophageal squamous cell carcinoma proteomics. *J Proteomics* 2012; 75: 3129-3137.
- [5] Samejima R, Kitajima Y, Yunotani S and Miyazaki K. Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma. *Anticancer Res* 1999; 19: 5515-5521.
- [6] Yamana H. [Molecular biology for esophageal squamous cell carcinoma]. *Nihon Rinsho* 2011; 69 Suppl 6: 51-56.
- [7] Dahmane N, Lee J, Robins P, Heller P and Ruiz i Altaba A. Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. *Nature* 1997; 389: 876-881.
- [8] Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piguat V, Beermann F and Ruiz IAA. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. *Proc Natl Acad Sci U S A* 2007; 104: 5895-5900.
- [9] Hogenson TL, Lauth M, Pasca diMagliano M and Fernandez-Zapico ME. Back to the drawing board: Re-thinking the role of GLI1 in pancreatic carcinogenesis. *F1000Res* 2014; 3: 238.
- [10] Ji Z, Mei FC, Xie J and Cheng X. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. *J Biol Chem* 2007; 282: 14048-14055.
- [11] Yoshikawa R, Nakano Y, Tao L, Koishi K, Matsumoto T, Sasako M, Tsujimura T, Hashimoto-Tamaoki T and Fujiwara Y. Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy. *Br J Cancer* 2008; 98: 1670-1674.
- [12] Yoon JW, Gallant M, Lamm ML, Iannaccone S, Vieux KF, Proytcheva M, Hyjek E, Iannaccone P and Walterhouse D. Noncanonical regulation of the Hedgehog mediator GLI1 by c-MYC in Burkitt lymphoma. *Mol Cancer Res* 2013; 11: 604-615.
- [13] Dahmane N, Sanchez P, Gitton Y, Palma V, Sun T, Beyna M, Weiner H and Ruiz i Altaba A. The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. *Development* 2001; 128: 5201-5212.
- [14] Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P and Ruiz i Altaba A. Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. *EMBO Mol Med* 2009; 1: 338-351.
- [15] Yan R, Peng X, Yuan X, Huang D, Chen J, Lu Q, Lv N and Luo S. Suppression of growth and migration by blocking the Hedgehog signaling pathway in gastric cancer cells. *Cell Oncol (Dordr)* 2013; 36: 421-435.
- [16] Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM and Beachy PA. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. *Nature* 2004; 431: 707-712.
- [17] Katoh Y and Katoh M. Hedgehog signaling pathway and gastrointestinal stem cell signaling network (review). *Int J Mol Med* 2006; 18: 1019-1023.
- [18] Mori Y, Okumura T, Tsunoda S, Sakai Y and Shimada Y. Gli-1 expression is associated with lymph node metastasis and tumor progression in esophageal squamous cell carcinoma. *Oncology* 2006; 70: 378-389.
- [19] Lu L, Wu M, Zhao F, Fu W, Li W, Li X and Liu T. Prognostic and clinicopathological value of Gli-1 expression in gastric cancer: a meta-analysis. *Oncotarget* 2016; 7: 69087-69096.
- [20] Marechal R, Bachet JB, Calomme A, Demetter P, Delpero JR, Svrcek M, Cros J, Bardier-Dupas A, Puleo F, Monges G, Hammel P, Louvet C, Paye F, Bachelier P, Le Treut YP, Vaillant JC, Sauvanet A, Andre T, Salmon I, Deviere J, Emile JF and Van Laethem JL. Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinoma. *Clin Cancer Res* 2015; 21: 1215-1224.
- [21] Xu L, Kwon YJ, Frolova N, Steg AD, Yuan K, Johnson MR, Grizzle WE, Desmond RA and Frost AR. Gli1 promotes cell survival and is predictive of a poor outcome in ERalpha-negative breast cancer. *Breast Cancer Res Treat* 2010; 123: 59-71.
- [22] Ciucci A, De Stefano I, Vellone VG, Lisi L, Bottoni C, Scambia G, Zannoni GF and Gallo D.

- Expression of the glioma-associated oncogene homolog 1 (gli1) in advanced serous ovarian cancer is associated with unfavorable overall survival. *PLoS One* 2013; 8: e60145.
- [23] Zhang J, Tu K, Yang W, Li C, Yao Y, Zheng X and Liu Q. Evaluation of Jagged2 and Gli1 expression and their correlation with prognosis in human hepatocellular carcinoma. *Mol Med Rep* 2014; 10: 749-754.
- [24] Zhou J, Zhu G, Huang J, Li L, Du Y, Gao Y, Wu D, Wang X, Hsieh JT, He D and Wu K. Non-canonical GLI1/2 activation by PI3K/AKT signaling in renal cell carcinoma: a novel potential therapeutic target. *Cancer Lett* 2016; 370: 313-323.
- [25] He HC, Chen JH, Chen XB, Qin GQ, Cai C, Liang YX, Han ZD, Dai QS, Chen YR, Zeng GH, Zhu JG, Jiang FN and Zhong WD. Expression of hedgehog pathway components is associated with bladder cancer progression and clinical outcome. *Pathol Oncol Res* 2012; 18: 349-355.
- [26] Rizvi S, Demars CJ, Comba A, Gainullin VG, Rizvi Z, Almada LL, Wang K, Lomberg G, Fernandez-Zapico ME and Buttar NS. Combinatorial chemoprevention reveals a novel smoothed-independent role of GLI1 in esophageal carcinogenesis. *Cancer Res* 2010; 70: 6787-6796.
- [27] Ma X, Sheng T, Zhang Y, Zhang X, He J, Huang S, Chen K, Sultz J, Adegboyega PA, Zhang H and Xie J. Hedgehog signaling is activated in subsets of esophageal cancers. *Int J Cancer* 2006; 118: 139-148.
- [28] Zhu W, You Z, Li T, Yu C, Tao G, Hu M and Chen X. Correlation of hedgehog signal activation with chemoradiotherapy sensitivity and survival in esophageal squamous cell carcinomas. *Jpn J Clin Oncol* 2011; 41: 386-393.
- [29] Isohata N, Aoyagi K, Mabuchi T, Daiko H, Fukaya M, Ohta H, Ogawa K, Yoshida T and Sasaki H. Hedgehog and epithelial-mesenchymal transition signaling in normal and malignant epithelial cells of the esophagus. *Int J Cancer* 2009; 125: 1212-1221.
- [30] Min S, Xiaoyan X, Fanghui P, Yamei W, Xiaoli Y and Feng W. The glioma-associated oncogene homolog 1 promotes epithelial-mesenchymal transition in human esophageal squamous cell cancer by inhibiting E-cadherin via Snail. *Cancer Gene Ther* 2013; 20: 379-385.
- [31] Gavert N and Ben-Ze'ev A. Epithelial-mesenchymal transition and the invasive potential of tumors. *Trends Mol Med* 2008; 14: 199-209.
- [32] Thiery JP, Acloque H, Huang RY and Nieto MA. Epithelial-mesenchymal transitions in development and disease. *Cell* 2009; 139: 871-890.
- [33] Parmar MK, Torri V and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. *Stat Med* 1998; 17: 2815-2834.
- [34] Williamson PR, Smith CT, Hutton JL and Marson AG. Aggregate data meta-analysis with time-to-event outcomes. *Stat Med* 2002; 21: 3337-3351.
- [35] Tierney JF, Stewart LA, Ghersi D, Burdett S and Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials* 2007; 8: 16.
- [36] Higgins JP, Thompson SG, Deeks JJ and Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; 327: 557-560.
- [37] Begg CB and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994; 50: 1088-1101.
- [38] Cui HW, Shi YX, Zhang M and Yang L. Expression of Hedgehog signaling molecules and their clinical significance in esophageal squamous cell carcinomas. *Medical Innovation of China* 2015; 12: 001-003.
- [39] Ju L, Zhen W and Zang DY. Expression and significance of Gli1 protein in the Hedgehog signaling pathway in esophageal squamous carcinoma. *Journal of Liaoning Medical University* 2013; 34: 008-009.
- [40] Li JP, Yang JP, Cui L, Li SL, Zhao ZH and Chen KS. Expression and significance of Smo and Gli1 mRNA in esophageal squamous cell carcinoma tissue. *Clinical Medicine* 2013; 33: 001-003.
- [41] Sun B, Zhang L, Li YX, Fu ZB, Shao HJ and Wen HT. Clinicopathological significance of expression of Smo and Gli1 in esophageal squamous cell carcinoma. *World Chinese Journal of Digestology* 2011; 19: 483-487.
- [42] Wei L and Xu Z. Cross-signaling among phosphoinositide-3 kinase, mitogen-activated protein kinase and sonic hedgehog pathways exists in esophageal cancer. *Int J Cancer* 2011; 129: 275-284.
- [43] Wei LY, Li DM, Qin T and Bao CE. The expression of Gli1 and its prognostic implication in patients with esophageal squamous cell carcinoma. *Modern Oncology* 2016; 24: 2881-2884.
- [44] Xiao F, Zhang WJ, Zhang J and Hu JG. The expression and clinical significance of gli1 protein in esophageal squamous cell carcinoma. *Journal of Taishan Medical College* 2016; 37: 121-123.
- [45] Yang Z, Cui Y, Ni W, Kim S and Xuan Y. Gli1, a potential regulator of esophageal cancer stem cell, is identified as an independent adverse prognostic factor in esophageal squamous cell carcinoma. *J Cancer Res Clin Oncol* 2017; 143: 243-254.
- [46] Dennler S, Andre J, Alexaki I, Li A, Magnaldo T, ten Dijke P, Wang XJ, Verrecchia F and Mauviel

- A. Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. *Cancer Res* 2007; 67: 6981-6986.
- [47] Stecca B and Ruiz i Altaba A. A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers. *EMBO J* 2009; 28: 663-676.
- [48] Aberger F and Ruiz IAA. Context-dependent signal integration by the GLI code: the oncogenic load, pathways, modifiers and implications for cancer therapy. *Semin Cell Dev Biol* 2014; 33: 93-104.
- [49] Cheng J, Gao J and Tao K. Corrigendum: Prognostic role of Gli1 expression in solid malignancies: a meta-analysis. *Sci Rep* 2016; 6: 27166.
- [50] Nishihira T, Hirayama K and Mori S. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. *Am J Surg* 1998; 175: 47-51.
- [51] Rizk N, Venkatraman E, Park B, Flores R, Bains MS and Rusch V. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. *J Thorac Cardiovasc Surg* 2006; 132: 1374-1381.